Pilot Grant Program

试点资助计划

• 批准号: 10618388
• 负责人: Daniel E Voth
• 金额: $ 22.8万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-05 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10618388
• 关键词: 2019-nCoV; Address; Anti-Infective Agents; Antibiotic Resistance; Area; Arkansas; Bacteria; Centers of Research Excellence; Clinical; Collaborations; Communicable Diseases; Development; Diagnostic Procedure; Elements; Ensure; Equation; Foundations; Funding; Goals; Grant; Growth; Health; Howard Temin Award; Human; Immune response; Immunology; Individual; Infection; Inflammatory Response; Institution; Medical; Medicine; Microbiology; Mission; National Institute of General Medical Sciences; Parasites; Pathogenesis; Pharmaceutical Preparations; Phase; Play; Predisposition; Prevalence; Property; Publications; Research; Research Infrastructure; Research Personnel; Research Support; Science; Scientist; Side; Therapeutic; Therapeutic Intervention; Universities; Variant; Virus; adverse outcome; antimicrobial drug; biomaterial development; comorbidity; improved; innovation; interest; microbial; novel; pathogen; pathogenic microbe; programs; prophylactic; recruit; recruitment science; resistant strain; response; success; vaccine development

PROJECT SUMMARY/ABSTRACT A primary means of research support for investigators in the Center for Microbial Pathogenesis and Host Inflammatory Responses (CMPHIR) in Phase III will be the NIGMS-funded Pilot Grant Program (PGP), supplemented with institutional funds ($100,000 per year for each year) to support a Director's Innovation Fund. The focus will be on identifying new investigators with research interests consistent with the scientific theme of the CMPHIR. Support will be provided for projects that clearly fit within the scientific scope of the CMPHIR, with a particular emphasis on investigators whose research is potentially synergistic with existing CMPHIR investigators, thereby maximizing opportunities for the development of synergistic collaborations. We will also continue the efforts we started in Phase II to support projects that address issues in infectious disease in the most comprehensive fashion possible and one that can be integrated with the experimental foundation built in Phases I and II. Included among specific areas of interest are projects investigating improved diagnostic methods, the development of more effective antimicrobial drugs, the potential to repurpose approved drugs for infectious disease applications, vaccine development, the development of biomaterials with anti-infective properties, and understanding the impact of host comorbidities on the susceptibility to infection and the response to therapeutic intervention. In addition, the PGP and Director's Innovation Fund will be used in support of highly strategic external recruitment by other research units at UAMS recruiting new investigators with research interests consistent with the scientific theme of the CMPHIR. This will allow the CMPHIR to continue to grow and mature into a self-sustaining Center of Biomedical Research Excellence as we move forward into Phase III and beyond.

项目总结/摘要 为微生物致病和宿主研究中心的研究人员提供研究支持的主要手段 炎症反应（CMPHIR）在第三阶段将是NIGMS资助的试点赠款计划（PGP）， 此外，还辅之以机构资金（每年100，000美元），以支持主任创新基金。 重点将是确定新的研究人员的研究兴趣与科学主题一致， CMPHIR。将为明确符合气候变化、海洋和自然资源影响评估科学范围的项目提供支持， 特别强调其研究可能与现有CMPHIR协同的研究者 研究人员，从而最大限度地提高发展协同合作的机会。我们还将 继续我们在第二阶段开始的努力，以支持解决传染病问题的项目， 最全面的方式可能和一个可以集成的实验基础， 一期及第二期感兴趣的具体领域包括研究改进诊断的项目 方法，开发更有效的抗微生物药物，重新使用已批准的药物的潜力， 传染病应用、疫苗开发、抗感染生物材料开发 性质，并了解宿主共病对感染易感性和反应的影响 到治疗干预。此外，PGP和董事创新基金将用于支持高度 UAMS的其他研究单位进行战略性外部招聘，招聘新的研究人员 与CMPHIR的科学主题相一致的利益。这将使CMPHIR继续增长， 成熟成为一个自我维持的生物医学研究卓越中心，因为我们进入第三阶段， 超越。